Back
Issues Notice to on PIL Challenging HPV Vaccination for Adolescent Girls
The on Wednesday issued notice to the in a that questions the and safety of the nationwide Human Papillomavirus (HPV) vaccination drive targeting adolescent girls. A Division Bench comprising Chief Justice Devendra Kumar Upadhyaya and Justice Tejas Karia directed the to place on record, within a week, all data pertaining to with the HPV vaccine. The court also appointed to assist in the matter, signalling the seriousness with which it views the petition.
The PIL, filed through advocate , contends that the rollout of the HPV vaccine—marketed as Gardasil—under the violates the of young girls under . The plea specifically invokes the principles of , , and , arguing that the government cannot compel vaccination without explicit and informed parental approval.
Constitutional Challenge and the Right to
At the heart of the petition lies the assertion that the HPV vaccination programme tramples upon the constitutional guarantee of . , which protects life and , has long been interpreted by the to include the right to and the freedom to make informed medical choices. The PIL argues that “ violates the of and under ,” and stresses that “no individual can be compelled to undergo vaccination or any other medical treatment without .”
The challenge gains further traction by linking the absence of to a direct breach of the right to life. The petitioners contend that administering a vaccine to minors—girls aged around 14 years—in schools and public health centres without prior discussion with guardians is not only unethical but legally untenable. The plea also invokes , suggesting that the vaccination mandate may interfere with the freedom of families to make private medical decisions.
Allegations of Procedural Lapses and Safety Concerns
The petition paints a disturbing picture of implementation. It claims that frontline health workers, including (ASHA workers), have been assigned enrolment targets, leading to undue pressure on young girls to receive the vaccine. This, the plea argues, renders the concept of meaningless and potentially coercive.
More alarmingly, the plea references specific instances of severe post-vaccination complications. It describes a case from Tamil Nadu where a 14-year-old girl allegedly developed “severe neurological symptoms, including loss of voice, paralysis-like weakness, inability to walk and blurred vision, within days of receiving the HPV vaccine in March this year.” Similar reported incidents from Gwalior in Madhya Pradesh and from Bihar have been cited to question the adequacy of the safety monitoring mechanism.
The petition also draws strength from a 2013 report of the . That committee had earlier flagged alleged irregularities in clinical trials of HPV vaccines Gardasil and Cervarix, pointing to “deviations from protocol and lapses in obtaining participants’ consent.” By invoking that parliamentary scrutiny, the PIL argues that the current programme has been launched without sufficient credible data on vaccine efficacy or an accurate assessment of the population’s actual medical needs.
On the international front, the petition highlights that , the manufacturer of Gardasil, had announced a global settlement exceeding $50 million to resolve more than 200 lawsuits alleging serious health complications following vaccination. These litigations, the plea submits, raise additional doubts about the vaccine’s long-term safety profile that have yet to be adequately addressed in the Indian context.
Court’s Intervention and the Government’s Response
During the hearing, Chief Justice Upadhyaya observed that the issues raised by the petition are “of a serious nature, particularly as they concern girl children.” The bench, without expressing any final view, promptly issued notice to the and fixed a tight deadline for the production of adverse event data. The appointment of further indicates the court’s intent to undertake a thorough examination of the scientific and legal dimensions of the vaccination programme.
The is now expected to submit not only the data on post-vaccination complications but also a detailed justification for the inclusion of the HPV vaccine in the . The government’s response will likely address the claims of insufficient , the alleged pressure tactics on health workers, and the scientific validity of the vaccine’s efficacy as compared to alternative cervical cancer prevention strategies.
Scientific Debate and Public Health Priorities
Beyond the constitutional questions, the PIL reignites the scientific debate over cervical cancer prevention. The petition asserts that “HPV infection is only one among several risk factors associated with cervical cancer” and that the long-term effectiveness of HPV vaccines remains uncertain. It advocates instead for regular screening of women between the ages of 30 and 65 as “the most effective strategy for preventing cervical cancer.”
This argument collides with the government’s public health stance, which views vaccination as a proactive measure to curb a disease that claims thousands of lives annually. The court’s eventual scrutiny will have to weigh these competing narratives, examining whether the vaccination programme is backed by sufficient domestic epidemiological evidence and whether resources might be better allocated to screening and early detection.
Implications for Vaccination Programmes and
The ’s intervention in this PIL could have far-reaching consequences. Should the court rule in favour of the petitioners, it may mandate a complete overhaul of the for all public immunisation drives, especially those targeting minors. A strong pronouncement on would reinforce the principle that even beneficial health interventions cannot be imposed without free and .
Conversely, a judgment upholding the vaccination programme would clarify the scope of in public health emergencies and routine care. It may delineate the boundaries within which the government can act to protect population health without infringing on individual liberties. For legal practitioners, the case is a critical addition to the evolving under , joining the ranks of end-of-life care, reproductive rights, and compulsory treatment cases.
The matter is scheduled for further hearing after the files its adverse event report. As the court navigates the intersection of public health, child rights, and constitutional guarantees, the outcome is poised to shape India’s vaccination policy and consent laws for years to come.
